Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexmarilimab - Faron Pharmaceuticals

Next Previous
X
Search
Drug Profile

Bexmarilimab - Faron Pharmaceuticals

Alternative Names: Anti-CLEVER-1 antibody - Faron Pharmaceuticals; Clevegen; FP 1305

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Faron Pharmaceuticals
  • Class Anti-infectives; Antineoplastics; Antituberculars; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Macrophage stimulants; STAB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours
  • No development reported Tuberculosis
  • Discontinued Immunocompromised infections; Pertussis

Most Recent Events

  • 10 Dec 2024 Updated efficacy and adverse event data from the phase-I/II BEXMAB trial in Myelodysplastic syndrome, Chronic myelomonocytic leukaemia and Acute myeloid leukaemia released by Faron Pharmaceuticals
  • 19 Apr 2024 Discontinued - Preclinical for Immunocompromised infections in Finland (IV) before April 2024 (Faron Pharmaceuticals pipeline, April 2024)
  • 19 Apr 2024 Discontinued - Preclinical for Pertussis in Finland (IV) before April 2024 (Faron Pharmaceuticals pipeline, April 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top